Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir

Background: The coronavirus 2019 (COVID-19) disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus led to a global pandemic. HCQ and FPV were used early in the pandemic as a treatment modality for COVID-19. Various studies evaluated the HCQ and FPV effectiveness, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Alosaimi, Bandar, Alshanbari, Huda M., Alturaiqy, Muath, AlRawi, Halah Z., Alamri, Saad, Albujaidy, Asma, Bin Sabaan, Aljawharah, Alrashed, Ahmed A., Alamer, Ahmad, Alghofaili, Fayez, Al-Duraymih, Khaled, Alshalani, Abdulaziz J., Alturaiki, Wael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785070/
https://www.ncbi.nlm.nih.gov/pubmed/36558907
http://dx.doi.org/10.3390/ph15121456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785070/
https://www.ncbi.nlm.nih.gov/pubmed/36558907
http://dx.doi.org/10.3390/ph15121456

Ejemplares similares